2nd ITP Update Day
8 October 2020
James B. Bussel, MD
Mention the words “immune thrombocytopenia” and the name Jim Bussel comes immediately to mind. Dr. Bussel, Emeritus Professor of Pediatrics, Medicine and Obstetrics and Gynecology at Weill Cornell Medicine in New York City, has focused his clinical and research interests throughout his distinguished career primarily on ITP and fetal and neonatal alloimmune thrombocytopenia (FNAIT). A graduate of Yale University and Columbia College of Physicians and Surgeons, Dr. Bussel completed a residency in pediatrics at Cincinnati Children’s Hospital and a fellowship in Pediatric Hematology-Oncology at Weill Cornell and Memorial Sloan Kettering Cancer Center. He has spent his professional life at Weill Cornell Medicine and has published more than 400 manuscripts largely on ITP and has been a principal investigator on numerous clinical trials on ITP in children and adults. Dr Bussel participated in the development of the first ASH ITP guideline and in the Consensus manuscript. In 2012 he was awarded the King Faisal Prize for Medicine, the so-called Arab Nobel prize.
Dr Nichola Cooper
Dr Nichola Cooper trained at Cambridge University and Barts and the London School of Medicine and Dentistry. She completed her haematology training at University College Hospital and subsequently gained research experience at Cornel Medical College, New York and the Institute of Child Health, University College London. Her areas of expertise are immunohaematology, autoimmune diseases, thrombocytopenia and immune thrombocytopenia (ITP). Dr Cooper has a clinical and laboratory research group focusing on immune haematology, in particular immune thrombocytopenia (ITP).
Alice Hart is a Clinical Research Fellow in non-malignant haematology and paediatric haematology working with Dr Nichola Cooper at Imperial College and Imperial College Healthcare NHS Trust. Her qualifications are MBBS, BSc, MRCP, FRCPath(Haem).
Alice has set up and is running a study performing susceptibility-weighted MRI brain scans on children with ITP to investigate whether they have cerebral microbleeds and whether this is associated with changes in cognitive function, HRQoL or fatigue. She is a co-investigator on the paediatric Romiplostim trial and the principle investigator for the TAPER study of Eltrombopag in adult ITP. She also has an interest in the pathological basis of ITP and other autoimmune haematological disorders as well as in patient and public involvement in research. She has presented at the international ITP preceptorship meeting, the Imperial BRC Imaging showcase and the Royal College of Paediatrics and Child Health benign haematology symposium.
Dr Quentin Hill BSc, MBChB, MRCP, FRCPath
Dr Hill graduated with a first class honours degree (BSc) 1995 followed by his medical degree (MBChB) in 1997. He completed his training in Yorkshire, UK in 2006 and since then, he has been a Consultant Haematologist at Leeds Teaching Hospitals NHS Trust where he leads for immune haematology and red cell disorders. He was appointed Honorary Clinical Associate Professor at the University of Leeds in 2017. He is joint editor of “Haematology in Critical Care: a Practical Handbook”, sits on the NIHR National Haematology Specialty Group, and currently chairs the UK ITP Forum.
David Kuter, MD, DPhil
David Kuter is Chief of Hematology at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School, both in Boston, USA. He received his undergraduate degree from Harvard College and his DPhil in Biochemistry while a Rhodes Scholar at Magdalen College, University of Oxford, UK, before obtaining his medical degree from Harvard Medical School. Dr Kuter divides his time between medical education of fellows and medical students, clinical care of patients with a wide range of haematological disorders, basic science investigation into thrombopoietin and megakaryocyte biology, and clinical research related to thrombopoietic agents and hemolytic anaemia. His basic science group was one of the laboratories that discovered thrombopoietin and his clinical research group carried out various seminal studies using thrombopoietic agents in transfusion medicine and ITP. A member of the American Society of Hematology (ASH), Professor Kuter is the recipient of a number of awards including the Irving London Teaching Award at Harvard Medical School, the Alfred Kranes Teaching Award at Massachusetts General Hospital, and the 2013 Earnest Beutler Award from ASH. He has given over 500 invited lectures in over 50 countries and served as a Visiting Professor in Beijing, Sydney, Tokyo, London, Durham, Melbourne and New Haven. Professor Kuter has authored or co-authored over 300 articles published in international, peer-reviewed journals including The New England Journal of Medicine, The Lancet and Blood.
Dr Vickie McDonald
Dr Vickie McDonald is a consultant haematologist with a specialist interest in coagulation and platelet disorders at the Royal London Hospital. She completed her haematology training at Guys and St Thomas’ NHS Foundation Trust and a PhD at University College London, following which she became a consultant in haemostasis and thrombosis at Guys and St Thomas’ NHS Foundation Trust in 2012. In 2017 she moved to the Royal London Hospital working with patients with inherited and acquired coagulation disorders but also taking the national lead for the UK ITP registry. She runs specialist clinics in ITP and is actively involved in several clinical trials in ITP, both early and late phase studies.
Marc Michel, M.D, M.Sc
Marc MICHEL, M.D, M.Sc, is a full Professor of Internal Medicine and the Head of the Unit of Internal Medicine, which is also the French national referral center for adult’s immune cytopenias (coordinator Prof B. Godeau), at Henri Mondor University Hospital, Université Paris-Est Créteil, Assistance Publique Hôpitaux de Paris, at Créteil, France. He is also the head of the Division of Internal Medicine – Geriatrics-Endocrinology and Emergency Unit, at Créteil.. He did his medical school, his residency and training in Paris (internal medicine, hematology and clinical immunology). He spent 2 years doing research in Immunology at INSERM U25, Faculté de Médecine Necker (Pr. Jean-François Bach) in Paris and spent a year at the Platelet research center (head Prof. JB Bussel) at the New York Presbyterian Hospital, Weill Medical College of Cornell University, New York. He has a recognized clinical expertise in auto-immune diseases and especially in ITP and autoimmune hemolytic anemias. He has participated as an investigator to several clinical trials and is an active member of both the European working group on thrombocytopenias and the international ITP working group. He has contributed to the development of new standards in ITP terminology and the consensual ITP bleeding assessment scale and He is the author or co-author of many peer-reviewed articles especially on adult’immune cytopenias. He has also an expertise in red blood cell disorders beside AIHA and especially in sickle cell anemia and in other acquired forms of hemolytic anemia such as paroxysmal nocturnal hemoglobinuria (PNH).
Guillaume Moulis, MD, PhD
Guillaume Moulis is Associate Professor in Internal Medicine at Toulouse University hospital, south of France. He obtained his medical degree in Toulouse, France. He gives care to patients with general symptoms, autoimmune diseases, and particularly non-malignant hematological diseases like ITP and AIHA, Toulouse University hospital being one of the French referral centers for autoimmune cytopenia. He is also a researcher in epidemiology and pharmacoepidemiology. He obtained his MSc and PhD degrees in pharmacoepidemiology in Bordeaux and Toulouse, respectively. He did a post-doctoral fellowship in epidemiology in Arrhus University, Denmark. He developed cohorts of patients with ITP and AIHA in France (CARMEN clinical registry; FAITH and AHEAD cohorts within the French national health database) to better understand ITP and AIHA epidemiology, as well as the use, effectiveness and safety of ITP and AIHA treatments in the real-world practice. Dr Guillaume Moulis has published 120+ research articles mostly in the field of non-malignant hematology (Blood, BJH, JTH…) and gives lectures on ITP epidemiology and management in the light of real-world data. He is founding member of the European Research Consortium on ITP (ERCI), in order to develop epidemiological and pharmacoepidemiological research on ITP at the European level.
Adrian Newland is Professor of Haematology at Barts Health National Health Service (NHS) Trust, London, UK. He has a research department within the Medical School, where he is a former Head of the Division of Haematology, Oncology and Imaging. Professor Newland has a particular interest in novel treatments and support therapy, and is involved in guideline development and a multidisciplinary approach to patient care. His clinical interests are in immune haematology and he jointly developed the National Registry for Immune Thrombocytopenia to collect comprehensive epidemiological and clinical data. Professor Newland’s group undertakes research into the molecular and immune basis of autoimmune disease and he has an active clinical research programme in novel treatments. He helped develop the ITP Clinical Network in the UK as a basis for clinical studies. Professor Newland co-chairs the WHO Strategic Advisory Group of experts on in-vitro diagnostics, is clinical advisor for pathology to NHS England and was President of the Royal College of Pathologists from 2005–2008 and the International Society of Hematology (ISH) from 2014–2016. Professor Newland is Senior Editor of Hematology, the journal of the ISH, and he has published over 300 peer-reviewed papers in international journals.
Drew Provan, MD, FRCP, FRCPath
Drew Provan is currently Emeritus Reader in Autoimmune Haematology at Barts and The London School of Medicine and Dentistry. Dr Provan studied molecular genetics at Leicester University before studying medicine. After junior medical posts in the UK, he undertook research at The Dana-Farber Cancer Institute from 1993-4 on an American Traveling fellowship awarded by the Medical Research Council.
Dr Provan took up the post of Consultant Haematologist in Southampton in 1995 and moved to Barts and The London in 2000. As a general haematologist, his main area of interest within the field of haematology is immunohaematology which includes diseases such as autoimmune thrombocytopenia (ITP), neutropenia and haemolytic anaemia. Dr Provan has established the UK ITP Registry (www.ukitpregistry.com) a clinical and laboratory database of patients with ITP. This facilitates the collection of clinical information related to adults with ITP throughout the UK, Europe and other countries, in addition to allowing for DNA samples to be obtained for genetic analysis, in an attempt to determine the underlying mechanisms leading to autoantibody production. This database is a potential tool for identifying surrogate markers of likely clinical outcomes and may allow for the identification of treatment response genes. Examining gene expression profiles in patients with ITP at various stages in the disease history, might allow for the identification of causal genes that may be over or underexpressed in patients with ITP.
Dr Provan, along with International colleagues published the consensus guidelines for the diagnosis and management of ITP in children and adults published in Blood.
Francesco Rodeghiero is currently the Scientific Director of the Hematology Project Foundation, a non-profit organization for scientific research based in Vicenza, Italy. Previously, he has directed for 23 years the Hematology Department of the San Bortolo Hospital in Vicenza. He has been Professor at the Postgratuated School of Hematology of the Verona University, Italy, for 26 years, leading a course on hemorrhagic and thrombotic disorders. He has been in the board of several national and international scientific societies, such as the Italiam Society of Hemostasis and Thrombosis, the European Hematology Association, the International Society on Thrombosis and Hemostasis – also as Chairman of its Scientific and Standardization Committee from 2002 to 2004 – and is currently member of the Scientific Committee of the Italian Society of Hematology. He’s consultant for the European Medicine Agency. He has been member of the Ethics Committee on drugs research and investigational protocol studies of the Vicenza District from 2006 to 2016. He has been conducting clinical research in the fields of hematology and hemostasis since the early 1970s. His main interests include thrombocytopenia, hemophilia, von Willebrand disease, thrombophilia, acute promyelocytic leukemia, myeloma, policytemia vera, and the epidemiological aspects of haematological diseases. In the last decades he mainly devoted to clinical research in the field of ITP. He is the author or co-author of more than 448 papers published in international, peer-reviewed journals.
Camelia Vladescu is currently a Clinical Research Practitioner at Imperial College NHS Trust in London, UK. In this role, she has been in charge of coordinating a multitude of interventional and observational studies in benign haematology. Her main area of interest is ITP and she participated and presented posters at various conferences, including EHA and international ITP Preceptorships. Recently she has worked on a project assessing cognitive health in patients with ITP as part of her Master of Clinical Research project.